Is Cencora, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is rated as risky with a P/E of 57.25.
Cencora's strong performance is further highlighted by its impressive return metrics, achieving a 44.51% return year-to-date compared to the S&P 500's 13.30%, and a remarkable 226.26% return over the past five years, slightly underperforming the S&P 500's 227.77% in the same period. Overall, these factors suggest that Cencora is fairly valued in the current market context.